Levels of Archaea in subgingival biofilm of subjects with periodontitis after periodontal treatment.

• Grant number: 11/16332-7
• Support Opportunities: Scholarships in Brazil - Master
• Effective date (Start): March 01, 2012
• Effective date (End): February 28, 2014
• Field of knowledge: Health Sciences - Dentistry - Periodontology
• Principal Investigator: Marcelo de Faveri
• Grantee: Fernanda Sampaio Ramiro
• Host Institution: Universidade de Guarulhos (UNG). Campus Guarulhos-Centro. Guarulhos , SP, Brazil

Abstract

Members of the Archaea domain can be detected in the microbiota of mucosal surfaces of humans and animals, but its association with disease has not been established. Several studies have found different levels of prevalence of this species in individuals with chronic and aggressive periodontitis. Recent studies by our research group reported a high prevalence of Archaea in subjects with generalized aggressive and chronic periodontitis, as well as in individuals with periodontal health. The mean level of Archaea in subjects with periodontal health was 0.5 ± 0.2 x 10(4) and in subjects with generalized aggressive periodontitis was 11.2 x 10(4) ± 6.6 (p <0 . 05), with statistically significant difference between groups (Mann Whitney, p <0.05). In addition, we found that microorganisms of the domain Archaea have a reduction in prevalence at 180 days post-treatment, regardless of the combination of amoxicillin and metronidazole with scaling and root planing. However, no study has evaluated the change in the levels of these microorganisms after periodontal therapy. Aim: To assess the levels of microorganisms in the domain Archaea before and after different modalities of periodontal therapy. Methods: Sixty individuals with chronic periodontitis (CP) will be selected and randomly assigned to three treatment groups: Control: Scaling and root planing (SRP); Test 1: RAR associated with metronidazole (400 mg / day for 14 days 3x) Test 2: RAR associated with metronidazole (400 mg / day for 14 days 3x) and amoxicillin (500 mg / 3x daily for 14 days). Individuals will be monitored clinically and microbiologically at baseline and 180 days post-therapy. Six samples of subgingival biofilm (3 PD <3 mm without bleeding on probing (BOP), and 3 with PD> 5 mm, with SS) will be collected. The samples will be analyzed by quantitative PCR using primers specific for the domain-domain Archaea. Differences between groups and within each group, among the experimental times are evaluated using the chi-square and Kruskal-Wallis statistical significance is set at 5%.